| 1.19 0.04 (3.48%) | 06-10 10:53 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.55 | 1-year : | 1.75 |
| Resists | First : | 1.32 | Second : | 1.5 |
| Pivot price | 1.25  |
|||
| Supports | First : | 1.04 | Second : | 0.87 |
| MAs | MA(5) : | 1.24 |
MA(20) : | 1.22 |
| MA(100) : | 1.13 |
MA(250) : | 1.29 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 28.6 |
D(3) : | 39.4 |
| RSI | RSI(14): 48.8 |
|||
| 52-week | High : | 3.82 | Low : | 0.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CGTX ] has closed above bottom band by 32.6%. Bollinger Bands are 13.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.23 - 1.24 | 1.24 - 1.25 |
| Low: | 1.1 - 1.11 | 1.11 - 1.12 |
| Close: | 1.13 - 1.15 | 1.15 - 1.16 |
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
Thu, 04 Jun 2026
Cognition Therapeutics advances zervimesine toward registrational DLB psychosis program; cash into Q2 2027 - TradingView
Thu, 04 Jun 2026
[8-K] COGNITION THERAPEUTICS INC Reports Material Event - Stock Titan
Tue, 02 Jun 2026
Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies? - Yahoo Finance
Mon, 01 Jun 2026
Neuro drug developer to outline DLB psychosis plans at June events - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 90 (M) |
| Shares Float | 82 (M) |
| Held by Insiders | 2.2 (%) |
| Held by Institutions | 23.4 (%) |
| Shares Short | 7,760 (K) |
| Shares Short P.Month | 7,320 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -5.24 |
| PEG Ratio | 0 |
| Price to Book value | 3.17 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|